ANAPTYSBIO, INC

Listed Company

ANABCIK 0001370053NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$234.60M

Net Income

—

Total Assets

—

Equity

—

Shares Out

29.10M

Op. Cash Flow

$19.70M

ANAB$57.97+117.32% · past yearDBEQ Basic

Daily closing prices

Business

Anaptysbio is a clinical-stage biotechnology company developing immunology therapeutics for autoimmune and inflammatory diseases. The company's pipeline includes rosnilimab (selective pathogenic T cell depleter, Phase 2b in rheumatoid arthritis), ANB033 (CD122 antagonist, Phase 1b in celiac disease and eosinophilic esophagitis), and ANB101 (BDCA2 modulator, Phase 1a). Anaptysbio also monetizes value from out-licensed programs: Jemperli (dostarlimab, PD-1 antagonist) partnered with GSK generating royalties, and imsidolimab (IL-36R antagonist) partnered with Vanda generating milestones and royalties.

Summary from 10-K filed 2026-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue	235	91	17	10	63
Research and development	136	164	132	89	98
General and administrative	51	42	42	37	21
Acquired in-process research and development	0	0	7	0	0
Total operating expenses	187	206	182	125	120
Income (loss) from operations	48	−115	−164	−115	−57
Interest income	13	20	19	8	431,000
Non-cash interest expense for the sale of future royalties	−80	−50	−18	−21	−1
Other income (expense), net	5	14,000	−2,000	12,000	37,000
Total other (expense) income, net	−61	−30	788,000	−14	−982,000
Loss before income taxes	−13	−145	−164	−129	−58
(Provision) benefit for income taxes	−164,000	−3,000	4,000	−24,000	0
Net loss	−13	−145	−164	−129	−58
Unrealized (loss) gain on available for sale securities	−329,000	1	4	−5	—
Comprehensive loss	−14	−144	−159	−134	−58
Basic (in dollars per share)	−0.46	−5.12	−6.08	−4.57	−2.11
Diluted (in dollars per share)	−0.46	−5.12	−6.08	−4.57	−2.11
Basic (in shares)	29	28	27	28	27
Diluted (in shares)	29	28	27	28	27

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	238	123	36	71	496
Receivables from collaborative partners	34	41	7	1	876,000
Short-term investments	73	262	355	370	52
Prepaid expenses and other current assets	5	6	9	5	5
Total current assets	350	432	407	447	554
Property and equipment, net	1	2	2	2	2
Operating lease right-of-use assets	13	14	16	18	20
Long-term investments	0	35	27	143	67
Other long-term assets	256,000	256,000	256,000	256,000	256,000
Total assets	364	484	452	610	643
Accounts payable	4	4	5	3	2
Accrued expenses	33	40	31	22	13
Current portion of operating lease liability	2	2	2	2	2
Total current liabilities	39	45	37	26	16
Liability related to sale of future royalties	277	353	311	304	251
Operating lease liability, net of current portion	12	14	16	18	19
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at December 31, 2025 and December 31, 2024, respectively	0	0	0	0	0
Common stock, $0.001 par value, 500,000 shares authorized, 28,019 shares and 30,473 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	28,000	30,000	27,000	29,000	28,000
Additional paid in capital	810	830	703	718	679
Accumulated other comprehensive (loss) gain	−24,000	305,000	−797,000	−5	−422,000
Accumulated deficit	−773	−759	−614	−450	−322
Total stockholders equity	37	71	88	262	356
Total liabilities and stockholders equity	364	484	452	610	643

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	559,000	606,000	652,000	675,000	619,000
Stock-based compensation	36	34	33	27	15
Accretion/amortization of investments, net	−5	−10	−11	−3	493,000
Amortization of right-of-use assets operating	2	2	2	2	1
Receivables from collaborative partners	7	−34	−5	−543,000	−876,000
Prepaid expenses and other assets	2	3	−4	−813,000	−2
Accounts payable and other liabilities	−87	−34	11	10	−5
Operating lease liabilities	−2	−2	−2	−2	−72,000
Net cash provided by (used in) operating activities	20	−135	−121	−74	−46
Purchase of investments	−196	−380	−304	−803	−119
Sales and maturities of investments	425	476	449	408	159
Purchases of property and equipment	−87,000	−358,000	−807,000	−358,000	−1
Net cash provided by investing activities	228	95	145	−395	39
Proceeds from public offerings, net of underwriters' fees	0	94	0	0	—
Proceeds from issuance of common stock	14	6	2	12	3
Proceeds from the sale of future royalties	0	50	0	35	250
Principal repayment of liability for sale of future royalties	−77	−15	−12	−2	0
Payments for repurchase of common stock	−69	−456,000	−50	0	0
Payment for net share settlement of equity awards	−1	−8	0	0	—
Payments for offering costs, net	0	−492,000	0	0	—
Payments for issuance costs related to the sale of future royalties	0	−103,000	−43,000	−336,000	−255,000
Net cash (used in) provided by financing activities	−133	127	−59	44	252
Net increase (decrease) in cash and cash equivalents	115	87	−35	−424	245
Interest portion of repayment for sale of future royalties	80	42	0	0	0
State income taxes paid	78,000	0	0	—	—
Amounts accrued for property and equipment	0	7,000	8,000	154,000	31,000
Amounts accrued for repurchase of common stock	382,000	0	456,000	0	0
Receivable related to issuance of common stock, upon exercise of stock options	29,000	0	−51,000	40,000	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ANAPTYSBIO, INC's CIK number?

ANAPTYSBIO, INC's SEC CIK number is 0001370053 (1370053). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ANAPTYSBIO, INC's SEC filings?

All of ANAPTYSBIO, INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did ANAPTYSBIO, INC last report earnings?

ANAPTYSBIO, INC (ANAB) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-219500). This is ANAPTYSBIO, INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is ANAPTYSBIO, INC's most recent earnings 8-K?

ANAPTYSBIO, INC's latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-219500. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View ANAPTYSBIO, INC's latest earnings 8-K →
Look up any company's CIK number →